[go: up one dir, main page]

BG91773A - Заместени на трето място производни на 2-оксиндола - Google Patents

Заместени на трето място производни на 2-оксиндола

Info

Publication number
BG91773A
BG91773A BG091773A BG9177390A BG91773A BG 91773 A BG91773 A BG 91773A BG 091773 A BG091773 A BG 091773A BG 9177390 A BG9177390 A BG 9177390A BG 91773 A BG91773 A BG 91773A
Authority
BG
Bulgaria
Prior art keywords
substituted
oxindole
derivatives
thirdly
oxindole derivatives
Prior art date
Application number
BG091773A
Other languages
English (en)
Other versions
BG60646B1 (bg
Inventor
Frederick Ehrgott
Carl Goddard
Gary Schulte
Original Assignee
Pfizer Inc., a corporation organized аnd existing under the laws of the State of Delaware
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc., a corporation organized аnd existing under the laws of the State of Delaware filed Critical Pfizer Inc., a corporation organized аnd existing under the laws of the State of Delaware
Publication of BG91773A publication Critical patent/BG91773A/bg
Publication of BG60646B1 publication Critical patent/BG60646B1/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)

Abstract

Съединенията са инхибитори на простагландин н2 синтетазата, 5-липоксигеназата и биосинтезата на интерлевкин-1 и могат да се използват като обезболяващи, противовъзпалителни и антиартритни средства при лечението на хронични възпалителни заболявания. Изобретението се отнася също така до фармацевтични състави, съдържащи 3-заместените производни на 2-оксиндола, до методи за инхибиране на простагландин н2-синтетазата и биосинтезата на интерлевкин-1 и до лечение на хронични възпалителни заболявания при бозайниците с помощта на посочените съединения. Освен това изобретението се отнася до някои нови карбоксилни киселини, полезни като междинни съединения при получаването на 3-заместените производни на 2-оксиндола и до метод за получаване на 3-заместените производни на 2-оксиндола. 18 претенции
BG91773A 1989-04-18 1990-04-16 Заместени на трето място производни на 2-оксиндола BG60646B1 (bg)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US34011389A 1989-04-18 1989-04-18

Publications (2)

Publication Number Publication Date
BG91773A true BG91773A (bg) 1993-12-24
BG60646B1 BG60646B1 (bg) 1995-11-30

Family

ID=23331948

Family Applications (1)

Application Number Title Priority Date Filing Date
BG91773A BG60646B1 (bg) 1989-04-18 1990-04-16 Заместени на трето място производни на 2-оксиндола

Country Status (33)

Country Link
US (4) US5047554A (bg)
EP (1) EP0393936B1 (bg)
JP (2) JP2506478B2 (bg)
KR (1) KR920006394B1 (bg)
CN (1) CN1022832C (bg)
AP (1) AP142A (bg)
AT (1) ATE118767T1 (bg)
AU (1) AU633767B2 (bg)
BG (1) BG60646B1 (bg)
CA (1) CA2014467C (bg)
CZ (1) CZ284340B6 (bg)
DD (1) DD293822A5 (bg)
DE (1) DE69017066T2 (bg)
DK (1) DK0393936T3 (bg)
EG (1) EG19122A (bg)
ES (1) ES2068334T3 (bg)
FI (1) FI106378B (bg)
GR (1) GR3015811T3 (bg)
HU (2) HUT58314A (bg)
IE (1) IE65091B1 (bg)
IL (3) IL110173A (bg)
IS (1) IS1636B (bg)
MA (1) MA21808A1 (bg)
MX (1) MX20359A (bg)
NO (1) NO176759C (bg)
NZ (1) NZ233320A (bg)
OA (1) OA09205A (bg)
PL (2) PL163941B1 (bg)
PT (1) PT93785B (bg)
RO (1) RO106402B1 (bg)
RU (2) RU2039042C1 (bg)
YU (1) YU47588B (bg)
ZA (1) ZA902871B (bg)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE68923673T2 (de) * 1988-10-18 1996-01-18 Pfizer Prodrogen von antiinflammatorischen 3-Acyl-2-oxindol-1-carboxamiden.
HU208421B (en) * 1988-10-18 1993-10-28 Pfizer Process for producing starting materials for producing 3-acyl-2-oxindol-carboxamides ofantiphlogistic activity
US5047554A (en) * 1989-04-18 1991-09-10 Pfizer Inc. 3-substituted-2-oxindole derivatives
IL95880A (en) * 1989-10-13 1995-12-31 Pfizer Use of 3-Transformed History of 2-Oxindole for the Preparation of Pharmaceuticals for Inhibition of Interlaukio-1 Biosynthesis
US5064851A (en) * 1990-07-24 1991-11-12 Pfizer Inc. 3-(1-substituted-pyrazoyl)-2-oxindole derivatives, compositions and use
TW438798B (en) * 1992-10-07 2001-06-07 Pfizer 3-substituted 2-oxindole-1-carboxamide pharmaceutical compositions
CZ131695A3 (en) * 1992-11-23 1996-05-15 Pfizer Process for preparing 4-chloro-2-thiophenecarboxylic acid, intermediates for its preparation and process for preparing 5-fluoro-6-chloro-3-(4-chloro-2-thenoyl)-2-oxindole-1-carboxamide
US5298522A (en) * 1993-01-22 1994-03-29 Pfizer Inc. 6-chloro-5-fluoro-3-(2-thenoyl)-2-oxindole-1-carboxamide as an analgesic and anti-inflammatory agent while maintaining a normal urine protein/creatinine ratio
JP2709530B2 (ja) * 1993-02-09 1998-02-04 ファイザー・インク． 抗炎症薬としてのオキシンドール１−［ｎ−（アルコキシカルボニル）］カルボキサミド類および１−（ｎ−カルボキサミド）カルボキサミド類
ES2076106B1 (es) * 1993-08-26 1996-06-16 Pfizer Composiciones farmaceuticas a base de 2-oxindol-1-carboxamidas 3-sustituidas
US5783664A (en) * 1993-09-17 1998-07-21 Smithkline Beecham Corporation Cytokine suppressive anit-inflammatory drug binding proteins
EP0679396A1 (en) * 1994-03-02 1995-11-02 Pfizer Inc. Use of 3-substituted-2-oxidole-1-carboxamides for the manufacture of a medicament in the treatment and prevention of ischemia induced myocardial injury and cytokine mediated myocardial injury
CN1051452C (zh) * 1994-07-26 2000-04-19 中国医学科学院血液学研究所 3-取代芳基氧化吲哚类化合物的应用
US5545656A (en) * 1995-04-05 1996-08-13 Pfizer Inc. 2-Oxidole-1-carboxamide pharmaceutical agents for the treatment of alzheimer's disease
WO1997022605A1 (en) * 1995-12-19 1997-06-26 Pfizer Inc. Stable, long acting salts of indole derivatives for the treatment of joint diseases
EP0826685A1 (en) * 1996-08-21 1998-03-04 Pfizer Inc. Stable, long acting salts of carboxamides for the treatment of joint disease
US6043379A (en) * 1997-04-04 2000-03-28 Pfizer Inc. Processes and intermediates for preparing 2-fluorothiophene derivatives
US6291514B1 (en) 1998-02-09 2001-09-18 3-Dimensional Pharmaceuticals, Inc. Heteroaryl amidines, methylamidines and guanidines, preparation thereof, and use thereof as protease inhibitors
US6649645B1 (en) * 1998-12-23 2003-11-18 Pharmacia Corporation Combination therapy of radiation and a COX-2 inhibitor for treatment of neoplasia
US6355648B1 (en) 1999-05-04 2002-03-12 American Home Products Corporation Thio-oxindole derivatives
PL211834B1 (pl) 2000-02-15 2012-06-29 Sugen Związki 2-indolinonowe, kompozycja farmaceutyczna je zawierająca oraz ich zastosowanie
AU2002230056A1 (en) * 2001-01-29 2002-08-12 Insight Strategy And Marketing Ltd Indole derivatives and their uses as heparanase inhibitors
AR042586A1 (es) * 2001-02-15 2005-06-29 Sugen Inc 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
WO2002070478A1 (en) * 2001-03-06 2002-09-12 Astrazeneca Ab Indolone derivatives having vascular-damaging activity
US6642232B2 (en) 2001-10-10 2003-11-04 Sugen, Inc. 3-[4-Substituted heterocyclyl)-pyrrol-2-ylmethylidene]-2- indolinone derivatives as kinase inhibitors
PL373523A1 (en) * 2002-04-22 2005-09-05 Pfizer Products Inc. Indol-2-ones as selective inhibitors of cyclooxygenase-2
MX2007014114A (es) 2005-05-10 2008-03-14 Intermune Inc Derivados de piridona para modular el sistema de proteina cinasa activada por estres.
CA2696609C (en) 2007-08-27 2017-09-05 Helicon Therapeutics, Inc. Therapeutic isoxazole compounds
US8304413B2 (en) 2008-06-03 2012-11-06 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
CN102413825A (zh) 2009-04-29 2012-04-11 阿马里纳股份公司 含有epa和心血管剂的药物组合物以及使用其的方法
US8933248B2 (en) 2012-06-21 2015-01-13 Council Of Scientific & Industrial Research 3-substituted-3-hydroxy oxindole derivatives and process for preparation thereof
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
CN106459042B (zh) 2014-04-02 2019-06-28 英特穆恩公司 抗纤维化吡啶酮类
CA2950084C (en) 2014-06-06 2022-04-19 Basf Se Use of substituted oxadiazoles for combating phytopathogenic fungi
WO2016150937A1 (en) 2015-03-25 2016-09-29 Lonza Ltd Method for preparation of thiophenecarbonyl chlorides
BR112018009539B1 (pt) 2015-11-13 2022-05-24 Basf Se Uso de compostos da fórmula i, compostos, mistura, composição agroquímica, uso dos compostos e método para combater fungos nocivos fitopatogênicos
AR106679A1 (es) 2015-11-13 2018-02-07 Basf Se Oxadiazoles sustituidos para combatir hongos fitopatógenos
KR20180083419A (ko) 2015-11-19 2018-07-20 바스프 에스이 식물병원성 진균을 퇴치하기 위한 치환 옥사디아졸
WO2017178245A1 (en) 2016-04-11 2017-10-19 Basf Se Substituted oxadiazoles for combating phytopathogenic fungi
CN108299354A (zh) * 2017-01-12 2018-07-20 中国科学院宁波材料技术与工程研究所 一种2,5-呋喃二甲酸或其酯化物的制备方法
CN115403566B (zh) * 2022-09-21 2024-01-30 山东大学 3-取代吲哚-2-酮化合物及其制备方法和应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1255658A (en) * 1917-11-12 1918-02-05 Adamson Stephens Mfg Co Carrier for belt conveyers.
BE756447A (fr) * 1969-10-15 1971-03-22 Pfizer Oxindolecarboxamides
US3900563A (en) * 1973-06-18 1975-08-19 American Cyanamid Co Method of using 3-(2-(4-phenyl-1-piperazinyl)ethyl)-indolines
US4721712A (en) * 1984-06-12 1988-01-26 Pfizer Inc. 1,3-disubstituted 2-oxindoles as analgesic and anti-inflammatory agents
US4556672A (en) * 1984-03-19 1985-12-03 Pfizer Inc. 3-Substituted 2-oxindole-1-carboxamides as analgesic and anti-inflammatory agents
IN162090B (bg) * 1984-03-19 1988-03-26 Pfizer
US4569942A (en) * 1984-05-04 1986-02-11 Pfizer Inc. N,3-Disubstituted 2-oxindole-1-carboxamides as analgesic and antiinflammatory agents
IN161509B (bg) * 1984-05-04 1987-12-19 Pfizer
US4695571A (en) * 1984-08-24 1987-09-22 Pfizer Inc. Tricyclic oxindole antiinflammatory agents
US4808601A (en) * 1984-09-19 1989-02-28 Pfizer Inc. Analgesic and antiinflammatory 1,3-diacyl-2-oxindole compounds
FI80270C (fi) * 1984-09-19 1990-05-10 Pfizer Foerfarande foer framstaellning av analgetiska och anti-inflammatoriska 1,3-diacyl-2-oxoindol-foereningar och mellanprodukter.
US4690943A (en) * 1984-09-19 1987-09-01 Pfizer Inc. Analgesic and antiinflammatory 1,3-diacyl-2-oxindole compounds
US4752609A (en) * 1985-06-20 1988-06-21 Pfizer Inc. Analgesic and antiinflammatory 1,3-diacyl-2-oxindole compounds
WO1988003658A1 (en) * 1986-11-14 1988-05-19 Kalervo Alfred August Hermas Lens for receiving and/or transmitting infrared radiation
US4962117A (en) * 1987-11-25 1990-10-09 Merck Frosst Canada, Inc. Heterazole dialkanoic acids
US4861794A (en) * 1988-04-13 1989-08-29 Pfizer Inc. 3-substituted-2-oxindole-1-carboxamides as inhibitors of interleukin-1 biosynthesis
US5047554A (en) * 1989-04-18 1991-09-10 Pfizer Inc. 3-substituted-2-oxindole derivatives

Also Published As

Publication number Publication date
PT93785A (pt) 1990-11-20
PL287812A1 (en) 1991-07-15
RU2039042C1 (ru) 1995-07-09
HUT58314A (en) 1992-02-28
CZ284340B6 (cs) 1998-10-14
EP0393936B1 (en) 1995-02-22
GR3015811T3 (en) 1995-07-31
CN1022832C (zh) 1993-11-24
NZ233320A (en) 1991-09-25
DE69017066D1 (de) 1995-03-30
KR920006394B1 (ko) 1992-08-06
DK0393936T3 (da) 1995-06-26
JP2581525B2 (ja) 1997-02-12
OA09205A (en) 1992-06-30
HU902462D0 (en) 1990-08-28
MA21808A1 (fr) 1990-12-31
ZA902871B (en) 1991-11-27
AU1051092A (en) 1992-04-09
ATE118767T1 (de) 1995-03-15
CN1046525A (zh) 1990-10-31
IS1636B (is) 1996-09-20
ES2068334T3 (es) 1995-04-16
KR900016189A (ko) 1990-11-12
BG60646B1 (bg) 1995-11-30
IL94047A (en) 1995-10-31
IL110173A (en) 1997-06-10
JP2506478B2 (ja) 1996-06-12
HU211150A9 (en) 1995-10-30
YU75590A (sh) 1992-07-20
NO176759C (no) 1995-05-24
EG19122A (en) 1994-07-30
IE65091B1 (en) 1995-10-04
PL284817A1 (en) 1991-03-25
AU621477B2 (en) 1992-03-12
NO901684D0 (no) 1990-04-17
CA2014467C (en) 2000-02-08
AP142A (en) 1991-09-26
CA2014467A1 (en) 1990-10-18
EP0393936A1 (en) 1990-10-24
PL163951B1 (pl) 1994-05-31
NO901684L (no) 1990-10-19
US6174883B1 (en) 2001-01-16
PT93785B (pt) 1996-09-30
JPH07118261A (ja) 1995-05-09
IL110173A0 (en) 1994-10-07
RU2073671C1 (ru) 1997-02-20
IE901360L (en) 1990-10-18
CZ184890A3 (cs) 1998-07-15
NO176759B (no) 1995-02-13
AP9000175A0 (en) 1990-04-30
AU5362690A (en) 1990-11-22
RO106402B1 (ro) 1993-04-30
US5290802A (en) 1994-03-01
JPH02292258A (ja) 1990-12-03
FI901915A0 (fi) 1990-04-17
MX20359A (es) 1994-02-28
IL94047A0 (en) 1991-01-31
IS3570A7 (is) 1990-10-19
DE69017066T2 (de) 1995-06-14
FI106378B (fi) 2001-01-31
AU633767B2 (en) 1993-02-04
YU47588B (sh) 1995-10-24
PL163941B1 (pl) 1994-05-31
US5047554A (en) 1991-09-10
US5919809A (en) 1999-07-06
DD293822A5 (de) 1991-09-12

Similar Documents

Publication Publication Date Title
BG91773A (bg) Заместени на трето място производни на 2-оксиндола
RO90952A (ro) Procedeu pentru prepararea unor derivati de 2-oxindol
ATE178044T1 (de) Inhibitoren des arginin-ketoamid-enzyms
MX9701893A (es) Nuevos inhibidores de la prostaglandinsintasa.
NL970035I2 (nl) Indool-derivaten.
FI906438A0 (fi) Menetelmä uusien, terapeuttisesti käyttökelpoisten A-nor-steroidi-3-karboksyylihappojohdannaisten valmistamiseksi
HUP0100156A2 (hu) Foszfolipáz-A2 inhibitor hatású indolszármazékok és alkalmazásuk gyógyászati készítmények előállítására
HK1039617A1 (en) Esters and amides of non-steroidal anti-inflammatory carboxylic acids which may be used as anti-oxidants, 5-lipoxygenase inhibitors and non-steroidal anti-inflammatory products.
RU94040859A (ru) Аминопроизводные оксо- и гидрокси-замещенных углеводородов, способы получения, фармацевтические композиции, способ ингибирования ретровирусной протеазы, способ лечения спида у млекопитающих
HUP0202381A2 (hu) MEK-inhibitor hatású fenil-amino-benzoesav-származékok alkalmazása krónikus fájdalom kezelésére szolgáló gyógyszerkészítmények előállítására
KR890001987A (ko) 테트라하이드로카바졸 1-알카노산
BR9712085A (pt) Inibidores de metaloprotease heterocìclicos
DK391289A (da) Indolderivater
BR9713178A (pt) Inbidores espirocìclicos da metaloprotease.
FI791670A (fi) Triazinderivat
NO873125D0 (no) Fremgangsmaate for fremstilling av antibakterielle forbindelser.
HUT52511A (en) Process for producing new substituted cephalosporine-sulfon derivatives and pharmaceutical compositions containing them as active components
MXPA02011269A (es) Compuestos de tienodibenzoazuleno como inhibidores del factor necrosis tumoral.
EA199800155A1 (ru) Новое соединение
EE9800230A (et) Difenüülstilbeenid kui COX-2 inhibiitorite eelravimid
EA199800701A1 (ru) БЕНЗО[С]ХИНОЛИЗИНОВЫЕ ПРОИЗВОДНЫЕ, ИХ ПОЛУЧЕНИЕ И ИСПОЛЬЗОВАНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ 5a-РЕДУКТАЗ
DK0540614T3 (da) 3-(1-substitueret pyrazoyl)-2-oxindolderivater
AU4613089A (en) Derivatives of 5-hydroxy and 5-methoxy 2-amino-pyrimidines as inhibitors of interleukin-1 production
GB1369577A (en) Indole-carboxylic acid derivatives
HUT50461A (en) Process for producing imidazole derivatives inhibiting dopamin-beta-hydroxylase and pharmaceutical compositions comprising such compounds